---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000034"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:16:54.458095+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Instil Bio reports Q4 net loss $1.99/share; ends ITIL-306 trial, closes UK facility

## Summary
- Cash and investments of $175.0M as of Dec 31, 2023, down from $260.9M a year earlier; runway expected beyond 2026.
- Q4 2023 net loss $1.99/share (GAAP), $1.26/share non-GAAP; full year net loss $24.00/share.
- R&D expenses fell to $2.0M in Q4 2023 from $20.7M in Q4 2022; restructuring/impairment charges totaled $72.0M for the year.
- Strategic collaboration announced for FRα-CoStAR TIL in NSCLC in China; ITIL-306 clinical trial stopped.
- Closed UK manufacturing facility; management exploring in-licensing/acquisition of novel therapies.

## SEC filing metadata
- accession: 0001789769-24-000034
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000034/0001789769-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000034/til-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000034
- JSON: https://secwatch.observer/filing/0001789769-24-000034.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000034.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000034/0001789769-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.